Proper determination of agonist efficacy is indispensable in the evaluation of agonist selectivity and bias to activation of specific signalling pathways. The operational model (OM) of pharmacological agonism is a useful means for achieving this goal. Allosteric ligands bind to receptors at sites that are distinct from those of endogenous agonists that interact with the orthosteric domain on the receptor. An allosteric modulator and an orthosteric agonist bind simultaneously to the receptor to form a ternary complex, where the allosteric modulator affects the binding affinity and operational efficacy of the agonist. Allosteric modulators are an intensively studied group of receptor ligands because of their selectivity and preservation of physiological space-time pattern of the signals they modulate. We analysed the operational model of allosterically-modulated agonism (OMAM) including modulation by allosteric agonists. Similar to OM, several parameters of OMAM are inter-dependent. We derived equations describing mutual relationships among parameters of the functional response and OMAM. We present a workflow for the robust fitting of OMAM to experimental data using derived equations.

Department of Experimental and Clinical Pharmacology University of Minnesota College of Pharmacy Minneapolis MN 55455 USA

Institute of Physiology CAS Vídeňská 1083 142 20 Prague Czech Republic

Zobrazit více v PubMed

Monod J, Changeux J, Jacob F. Allosteric proteins and cellular control systems. J. Mol. Biol. 1963;6:306–329. doi: 10.1016/S0022-2836(63)80091-1. PubMed DOI

Liu J, Nussinov R. Allostery: an overview of its history, concepts, methods, and applications. PLoS Comput. Biol. 2016;12:e1004966. doi: 10.1371/journal.pcbi.1004966. PubMed DOI PMC

Wodak SJ, et al. Allostery in its many disguises: from theory to applications. Structure. 2019;27:566–578. doi: 10.1016/j.str.2019.01.003. PubMed DOI PMC

Bhat AS, Dustin Schaeffer R, Kinch L, Medvedev KE, Grishin NV. Recent advances suggest increased influence of selective pressure in allostery. Curr. Opin. Struct. Biol. 2020;62:183–188. doi: 10.1016/j.sbi.2020.02.004. PubMed DOI PMC

Zhang Y, et al. Intrinsic dynamics is evolutionarily optimized to enable allosteric behavior. Curr. Opin. Struct. Biol. 2020;62:14–21. doi: 10.1016/j.sbi.2019.11.002. PubMed DOI PMC

Lazareno S, Dolezal V, Popham A, Birdsall NJM. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004;65:257–266. doi: 10.1124/mol.65.1.257. PubMed DOI

De Amici M, Dallanoce C, Holzgrabe U, Tränkle C, Mohr K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med. Res. Rev. 2010;30:463–549. doi: 10.1002/med.20166. PubMed DOI

May LT, Leach K, Sexton PM, Christopoulos A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007;47:1–51. doi: 10.1146/annurev.pharmtox.47.120505.105159. PubMed DOI

Foster DJ, Conn PJ. Allosteric modulation of GPCRs: new insights and potential utility for treatment of schizophrenia and other CNS disorders. Neuron. 2017;94:431–446. doi: 10.1016/j.neuron.2017.03.016. PubMed DOI PMC

Wold EA, Chen J, Cunningham KA, Zhou J. Allosteric modulation of class A GPCRs: targets, agents, and emerging concepts. J. Med. Chem. 2019;62:88–127. doi: 10.1021/acs.jmedchem.8b00875. PubMed DOI PMC

Guarnera E, Berezovsky IN. On the perturbation nature of allostery: sites, mutations, and signal modulation. Curr. Opin. Struct. Biol. 2019;56:18–27. doi: 10.1016/j.sbi.2018.10.008. PubMed DOI

Guarnera E, Berezovsky IN. Allosteric drugs and mutations: chances, challenges, and necessity. Curr. Opin. Struct. Biol. 2020;62:149–157. doi: 10.1016/j.sbi.2020.01.010. PubMed DOI

Black JW, Leff P. Operational models of pharmacological agonism. Proc. R Soc. Lond. Ser. B Biol. Sci. 1983;220:141–162. doi: 10.1098/rspb.1983.0093. PubMed DOI

Leff P, Dougall IG, Harper D. Estimation of partial agonist affinity by interaction with a full agonist: a direct operational model fitting approach. Br. J. Pharmacol. 1993;110:239–244. doi: 10.1111/j.1476-5381.1993.tb13799.x. PubMed DOI PMC

Jakubík J, et al. Applications and limitations of fitting of the operational model to determine relative efficacies of agonists. Sci. Rep. 2019;9:4637. doi: 10.1038/s41598-019-40993-w. PubMed DOI PMC

Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model I. Model description. J. Theor. Biol. 1996;178:151–167. doi: 10.1006/jtbi.1996.0014. PubMed DOI

Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 2007;28:382–389. doi: 10.1016/j.tips.2007.06.004. PubMed DOI

Jakubík J, Bacáková L, Lisá V, El-Fakahany EE, Tucek S. Activation of muscarinic acetylcholine receptors via their allosteric binding sites. Proc. Natl. Acad. Sci. USA. 1996;93:8705–8709. doi: 10.1073/pnas.93.16.8705. PubMed DOI PMC

Langmead CJ, et al. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol. Pharmacol. 2006;69:236–246. doi: 10.1124/mol.105.017814. PubMed DOI

Bridges TM, et al. Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: exploration of alternative benzyl and privileged structure moieties. Bioorg. Med. Chem. Lett. 2008;18:5439–5442. doi: 10.1016/j.bmcl.2008.09.023. PubMed DOI PMC

Digby GJ, et al. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J. Neurosci. 2012;32:8532–8544. doi: 10.1523/JNEUROSCI.0337-12.2012. PubMed DOI PMC

Noetzel MJ, et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol. Pharmacol. 2012;81:120–133. doi: 10.1124/mol.111.075184. PubMed DOI PMC

Koole C, et al. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J. Biol. Chem. 2012;287:3659–3673. doi: 10.1074/jbc.M111.309369. PubMed DOI PMC

Stanczyk MA, et al. The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist. Br. J. Pharmacol. 2019;176:1649–1663. doi: 10.1111/bph.14602. PubMed DOI PMC

Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model II. Understanding apparent affinity. J. Theor. Biol. 1996;178:169–182. doi: 10.1006/jtbi.1996.0015. PubMed DOI

Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model III. Resurrecting efficacy. J. Theor. Biol. 1996;181:381–397. doi: 10.1006/jtbi.1996.0139. PubMed DOI

Jakubík J, El-Fakahany EE. Allosteric Modulation of Muscarinic Receptors. In: Myslivecek J, Jakubik J, editors. Muscarinic Receptor: From Structure to Animal Models. Totowa: Humana Press; 2016. pp. 95–130.

Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 1988;33:187–194. PubMed

Burger WAC, Sexton PM, Christopoulos A, Thal DM. Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors. J. Gen. Physiol. 2018;150:1360–1372. doi: 10.1085/jgp.201711979. PubMed DOI PMC

Jakubík J, Bacáková L, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 1997;52:172–179. doi: 10.1124/mol.52.1.172. PubMed DOI

Jakubík J, Randáková A, El-Fakahany EE, Doležal V. Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators. PLoS ONE. 2019;14:e0214255. doi: 10.1371/journal.pone.0214255. PubMed DOI PMC

Jakubík J, Janíčková H, El-Fakahany EE, Doležal V. Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. Br. J. Pharmacol. 2011;162:1029–1044. doi: 10.1111/j.1476-5381.2010.01081.x. PubMed DOI PMC

El-Fakahany EE, Jakubik J. Radioligand binding at muscarinic receptors. In: Myslivecek J, Jakubik J, editors. Muscarinic Receptor: From Structure to Animal Models. Totowa: Humana Press; 2016. pp. 37–68.

A critical re-evaluation of the slope factor of the operational model of agonism: When to exponentiate operational efficacy

Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

Allosteric Modulation of GPCRs of Class A by Cholesterol